Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent. Merck said the treatments when used as the initial treatment for advanced renal cell carcinoma (RCC) reduced the risk of death by about 47 percent in its late-stage trial. Keytruda has been Merck's most important growth driver with its domination of the lucrative lung cancer space, and shows no sign of slowing as it produces positive clinical data and adds approvals for different types of cancer.
SLAC-Stanford partnership lauded
Why Mushrooms Are Good For You and Why You Should Eat More of Them
Hybrid Systems, BayWa reap Australian microgrid contracts
JinkoSolar taps Daqo for high-purity polysilicon
Elections to dictate success of Spain’s 100 percent -renewable push
FERC takes a firm stand in PG&E bankruptcy filing
Direct Energy signs PPA for 75-MW solar array in California